| Literature DB >> 32477146 |
Yin-Sir Chung1,2, Brandon Kar Meng Choo1, Pervaiz Khalid Ahmed3,4, Iekhsan Othman1,2, Mohd Farooq Shaikh1.
Abstract
Orthosiphon stamineus (OS) or Orthosiphon aristatus var. aristatus (OAA) is commonly known as cat's whiskers or "misai kucing". It is an herbaceous shrub that is popular in many different traditional and complementary medicinal systems. Its popularity has been justified by the plethora of studies that have shown that the secondary metabolites of the plant has effects that range from anti-inflammatory and gastroprotective to anorexic and antihypertensive. As such, OS could also be a potential treatment for Central Nervous System (CNS) disorders. However, a cohesive synthesis of the protective actions of OS was lacking. This systematic review was therefore commenced to elaborate on the various protective mechanisms of OS in the CNS. The PRISMA model was used and five databases (Google Scholar, SCOPUS, SpringerLink, ScienceDirect, and PubMed) were searched with relevant keywords to finally identify four articles that met the inclusion criteria. The articles described the protective effects of OS extracts on Alzheimer's disease, epilepsy, learning and memory, oxidative stress, and neurotoxicity. All the articles found were experimental or preclinical studies on animal models or in vitro systems. The reported activities demonstrated that OS could be a potential neuroprotective agent and might improve CNS conditions like neurodegeneration, neuroinflammation, and oxidative stress.Entities:
Keywords: Orthosiphon stamineus; central nervous system; neuroprotection; neurotoxicity; oxidative stress
Year: 2020 PMID: 32477146 PMCID: PMC7237571 DOI: 10.3389/fphar.2020.00692
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1Flow chart of the study selection criteria based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Summary of studies reported for neuroprotective effects of Orthosiphon stamineus Benth.
| Study details | Study design and model | Testing dose | Active constituents | Administration route | Pharmacological actions | Summary of findings |
|---|---|---|---|---|---|---|
|
| 50, 100 and 200 mg/kg | Not mentioned | Oral and intraperitoneal (i.p., at a volume corresponding to 0.1 mL/100 g of b.w.) | Anti-AD | Ethanolic extract of OS might be a promising candidate as a memory enhancer or as a therapeutic treatment for neurodegenerative diseases like AD | |
|
| 50, 100 and 200 mg/L | Not mentioned | Oral | Anti-convulsive and anti-inflammatory | Ethanolic leaf extract of OS has the potential to be a novel symptomatic treatment for epileptic seizures as it is pharmacologically active against seizures in the zebrafish | |
|
| For human recombinant HEK-293 cells and Wistar rat vas deferens adult male Sprague Dawley (3-mo, 200 – 250 g) and juvenile male SD rats (35–40-do, 75 –100 g) | A2A binding assay: | ombuin (3,3′,5-trihydroxy-4′,7-dimethoxyflavone) (0.14%),3′-hydroxy-4′,5,6,7-tetramethoxyflavone (0.10%), sinensetin (0.07%), orthosiphol B (0.26%), orthosiphol A (0.67%), staminol A (0.45%), orthosiphonone A (0.12%) | Oral and intraperitoneal | Enhanced learning and memory | Standardised ethanolic extract of OS may reverse age-related deficits in short-term social memory and can be considered to prevent or decrease the rate of neurodegeneration |
|
| 0.01 to 1 mg/mL | Not mentioned | N/A | Antioxidative, antiapoptotic and neuroprotective to alleviate ROS-mediated dysfunction of dopamenergic neurons and neuronal cell death | OS methanol bioactive guided fraction (OMF) can attenuate the H2O2 induced oxidative stress by improving the antioxidant status, cell viability, ROS formation, mitochondrial membrane integrity and regulation of gene expression in the neuronal cells. OMF can be considered as an alternative to some of the toxic synthetic antioxidants which are used in food, cosmetics and pharmaceutical applications |
AD, Alzheimer’s Disease; BDNF, brain-derived neurotrophic factor; b.w., body weight; CREB, cAMP response element binding protein; do, day-old; i.p., intraperitoneal; mo, month-old; OS, Orthosiphon stamineus; p.o., per oral; SD, Sprague Dawley; TrKB, Tropomyosin receptor kinase B.
Figure 2Principal chemical constituents of Orthosiphon stamineus.
Summary table of the preparations used by the studies in the present systematic literature review.
| Study | Formulation | Source | Species, concentration | Quality control reported? (Y/N) | Chemical analysis reported? (Y/N) |
|---|---|---|---|---|---|
|
| 50% ethanolic extract | NatureCeuticals Sdn Bhd, Kedah DA, Malaysia | Y- Prepared in a Good Manufacturing Practice (GMP) based environment | N | |
|
| 50% ethanolic extract | NatureCeuticals Sdn Bhd, Kedah DA, Malaysia | N | N | |
|
| 70% ethanolic extract | Prepared by | Y - Plant material identified by a taxonomist on the basis of exomorphic characters and literature review | Y - HPLC | |
|
| Methanolic fraction | Prepared by | Y - Plant material authenticated at Acharya Nagarjuna University, Guntur, India | Y - HPLC |
Figure 3Mechanism of action of Orthosiphon stamineus in CNS disorders.